| Creekside Center For Rehabilitation And Healing | |
| 306 W Due West Avenue, Madison, Tennessee 37115 | |
| (615) 612-4499 | |
| Name | Creekside Center For Rehabilitation And Healing |
|---|---|
| Location | 306 W Due West Avenue, Madison, Tennessee |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 139 |
| Occupancy Rate | 83.96% |
| Medicare ID (CCN) | 445516 |
| Legal Business Name | Madison Pointe Center For Rehabilitation And Healing Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1104250406 |
| Organization Name | CREEKSIDE HEALTHCARE, LLC |
| Doing Business As | CREEKSIDE HEALTH AND REHABILITATION CENTER |
| Address | 306 W Due West Ave, Madison, TN 37115 |
| Phone Number | 615-612-4499 |
News Archive
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
The discovery by Australian Scientists of a gene that appears to be linked to blood vessel growth in tumours in mice, may one day lead to better treatments for cancer in people.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
We control their electrical activity. Cardiac cells are capable of producing and transmitting electric signals through changes in a cell membrane potential.
› Verified 3 days ago
| NPI Number | 1538656939 |
| Organization Name | MADISON POINTE CENTER FOR REHABILITATION AND HEALING LLC |
| Address | 306 W Due West Ave, Madison, TN 37115 |
| Phone Number | 615-612-4499 |
News Archive
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
The discovery by Australian Scientists of a gene that appears to be linked to blood vessel growth in tumours in mice, may one day lead to better treatments for cancer in people.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
We control their electrical activity. Cardiac cells are capable of producing and transmitting electric signals through changes in a cell membrane potential.
› Verified 3 days ago
| NPI Number | 1750360152 |
| Organization Name | IMPERIAL MANOR CONVALESCENT CENTER LLC |
| Doing Business As | IMPERIAL GARDENS HEALTH AND REHABILITATION |
| Address | 306 W Due West Ave, Madison, TN 37115 |
| Phone Number | 615-865-5001 |
News Archive
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
The discovery by Australian Scientists of a gene that appears to be linked to blood vessel growth in tumours in mice, may one day lead to better treatments for cancer in people.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
We control their electrical activity. Cardiac cells are capable of producing and transmitting electric signals through changes in a cell membrane potential.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
The discovery by Australian Scientists of a gene that appears to be linked to blood vessel growth in tumours in mice, may one day lead to better treatments for cancer in people.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
We control their electrical activity. Cardiac cells are capable of producing and transmitting electric signals through changes in a cell membrane potential.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $7400 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.48 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.3 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 56.64 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.47 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 7.75 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.2 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 60.55 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 5.8 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 76.28 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.36 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 34.56 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.51 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.89 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.18 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 81.39 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 85.28 | 82.93 |
News Archive
That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.
The discovery by Australian Scientists of a gene that appears to be linked to blood vessel growth in tumours in mice, may one day lead to better treatments for cancer in people.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
We control their electrical activity. Cardiac cells are capable of producing and transmitting electric signals through changes in a cell membrane potential.
› Verified 3 days ago
Signature Healthcare Of Madison Location: 431 Larkin Spring Rd, Madison, Tennessee 37115 Phone: (615) 865-8520 | |
Creekside Center For Rehabilitation And Healing Location: 306 W Due West Avenue, Madison, Tennessee 37115 Phone: (615) 612-4499 |